The mechanism by which ocular surface squamous neoplasia (OSSN) responds to topical interferon-alpha-2b (IFNa2b) is not known. We report the cases of 3 immunosuppressed patients whose tumors did not respond to topical IFNa2b therapy. The purpose of this series is to shed light on potential mechanisms of IFNa2b in OSSN.
O cular surface squamous neoplasia (OSSN) includes a spectrum of epithelial squamous malignancies, ranging from dysplasia to invasive carcinoma, and is more commonly found in older, white males. Treatment options for OSSN include a surgical excision with a no-touch technique and cryotherapy and medical therapy with mitomycin-C (MMC), 5-fluorouracil (5-FU), or interferon-alpha-2b (IFNa2b). Topical IFNa2b is favored given its high success rate (;80% of tumors completely respond to therapy) and minimal toxicity. Conversely, up to 20% of tumors do not respond to IFNa2b, and it is currently not possible to predict which patients will fail treatment. [1] [2] [3] Interferon signaling exerts multiple activities including antiviral, cytotoxic, antiangiogenic, antiproliferative, immune-modulatory, and enhanced host antitumor surveillance. 4, 5 The exact mechanism by which interferon acts on OSSN, however, is largely unknown. This leaves opportunity for continued investigation of interferon's actions on OSSN in an effort to better guide therapeutic decisions, such as pursuing a surgical approach directly, or using a different agent in patients in whom interferon is less likely to be effective. In this study, we present 3 patients with various causes of immunosuppression in whom topical IFNa2b was not effective in treating OSSN. The purpose of this case series is to propose the idea that perhaps an intact immune system is a key player in interferon's therapeutic effects on OSSN.
METHODS
This retrospective study was approved by the institutional review boards of the Miami Veterans Affairs Hospital and the University of Miami. The methods adhered to the tenets of the Declaration of Helsinki and were compliant with the Health Insurance Portability and Accountability Act. The medical records of 10 patients with biopsy-proven OSSN who presented to Bascom Palmer Eye Institute and the Miami Veterans Affairs Hospital between September 2010 and July 2016 and who received topical IFNa2b with incomplete resolution of the tumor were reviewed. Of these patients, 3 were found to have various causes of immunosuppression, including lymphoma on rituximab therapy, leukemia, and multiple myeloma.
Patient records were reviewed for demographic information (age, race, and ethnicity), comorbidities, and OSSN characteristics (eye, location, size, involved ocular structures, appearance, and pathologic grading of the tumor). Documented treatment information included dose, frequency, length of IFNa2b treatment, and subsequent therapy after IFNa2b failure.
RESULTS
Three cases were identified of immunosuppressed patients whose OSSN did not respond to initial treatment with topical IFNa2b therapy.
Case 1
A 66-year-old man had a medical history of anemia, diabetes, and history of low-grade non-Hodgkin follicular lowgrade B-cell lymphoma diagnosed in 1988, after allogeneic bone marrow transplantation. Recurrent lymphoma was noted on surveillance 14 years later in the lacrimal gland with involvement of mediastinal and abdominal lymph nodes, prompting treatment with rituximab. While receiving treatment, the patient presented to the Miami Veterans Affairs (VA) eye clinic for evaluation of conjunctival lesions in both eyes. Best-corrected visual acuity (BCVA) was 20/30-2 in the right eye and 20/25 in the left eye. Slit-lamp examination revealed a gelatinous limbal lesion in the right eye extending from the 7:30 to 10 o'clock position with 1-mm extension into the cornea (Fig. 1A ). In the left eye, opacity involving the limbus and cornea was noted at approximately the 4 o'clock position (Fig. 1B) . Anterior segment high-resolution ocular coherence tomography (HR-OCT) demonstrated a thick hyperreflective epithelium with a sharp border between normal and abnormal epithelium, consistent with OSSN in both eyes (Fig. 1C) . The patient elected empiric therapy with IFNa2b (1 million units/ mL), 1 drop 4 times daily in both eyes. Despite 6 months of therapy, persistent OSSN was noted in both eyes (Fig. 1D, E ). An incisional conjunctival biopsy was performed in the left eye, which confirmed the diagnosis of OSSN with severe dysplasia. The patient was administered 5-FU 1% four times daily. After 2 cycles (1 wk on, 3 wks off), clinical and OCT evaluation were consistent with resolved OSSN in both eyes.
Case 2
A 69-year-old man with newly diagnosed leukemia (not yet treated), diabetes mellitus (hemoglobin A1c 8.8), atrial fibrillation, and hypertension presented to the eye clinic with a right temporal conjunctival lesion. BCVA was 20/25 in the right eye and 20/30 in the left eye. Slit-lamp examination revealed a gelatinous lesion with foci of leukoplakia in the temporal conjunctiva of the right eye ( Fig. 2A) . HR-OCT demonstrated typical features of OSSN (Fig. 2B ). An incisional biopsy confirmed the diagnosis of OSSN with severe dysplasia. The patient elected therapy with IFNa2b (1 million units/mL), 1 drop 4 times daily. After 2 months of therapy, the lesion was noted to have grown slightly (Fig. 2C ). As such, the patient was switched to 5-FU 1% four times daily (1 wk on, 3 wks off). After 4 cycles, complete resolution of the OSSN was noted.
Case 3
A 76-year-old white man had a medical history of multiple myeloma treated with lenalidomide 25 mg for the last 6 years. He presented to the eye clinic for evaluation of the conjunctival lesion in the right eye. BCVA was 20/30 in the right eye and 20/100 in the left eye. Ocular pressure was normal. Slit-lamp examination revealed a gelatinous limbal lesion in the right eye extending from the 3 to 5 o'clock position with 3-mm extension into the cornea (Fig. 3A) .
Anterior segment HR-OCT demonstrated thick hyperreflective epithelium extending throughout the cornea and conjunctiva, consistent with OSSN (Fig. 3B) . The patient elected empiric therapy with IFNa2b (1 million units/mL), 1 drop 4 times daily. Despite 7 months of therapy, persistent OSSN was noted (Fig. 3C ). As such, an incisional conjunctival biopsy was performed, which confirmed OSSN with severe dysplasia. The patient was administered 5-FU 1% four times daily. After 2 cycles (1 wk on, 3 wks off), he demonstrated a very slow response. He was therefore administered MMC 0.04% four times daily. After 4 cycles of this therapy (1 wk on, 3 wks off), clinical and OCT evaluations (Fig. 3D) were consistent with resolved OSSN.
DISCUSSION
We report the cases of 3 patients with immunosuppression of various causes whose OSSN did not resolve with initial treatment with topical interferon therapy. This suggests that perhaps an intact immune response is necessary for interferon to act therapeutically on OSSN. Although the detailed mechanism by which interferon acts on OSSN is not known, it is likely that interferon can cause T-cell-and macrophage-induced apoptosis in OSSN. Furthermore, knowledge on its mechanism of action can be gleaned from its biomolecular roles, and other models in which interferon is used therapeutically, namely in hepatitis C and cervical intraepithelial neoplasia.
Clinical immunosuppression has been found to be a limitation in achieving therapeutic efficacy of interferon in hepatitis C treatment. One study found that in patients coinfected with hepatitis C and HIV, a lower CD4 + cell count was associated with a poorer response to therapy. 6 Other immunological factors implicated in an inadequate hepatitis C response to interferon include alcohol intake, drug use, low weight, old age, and diabetes. Interestingly, elevated levels of IL-6, IL-8, IL-10, IL-1b, and TNFa, among other immunological disturbances, have been associated with a poor response to IFNa therapy. 7 Together, this points to a complex interface between interferon and the rest of the immune system.
In cervical intraepithelial neoplasia, factors such as current smoking, lower Th1-cell-derived interleukins, and decreased NK cell activity have been associated with poorer tumor resolution with IFNa treatment. 8, 9 Similarly to hepatitis C, higher levels of inflammatory modulators such as IL-4, IL-10, and TGF-b, as well as an increase in lymphocytes expressing regulatory T-cell marker FOXP3, were all associated with poorer treatment outcomes. 4, 5, 9 As such, it may be true that tumor regression in OSSN depends on a certain immunity profile.
Interferon acts as an immunomodulatory agent that is involved in intrinsic crosstalk between almost all other players in the immune system. 5 Various ligands activate a set of pattern recognition receptors, including Toll-like receptors (TLRs), which generate type I interferons and various cytokines such as IL-12 and IL-15. 1 This initiates apoptotic pathways through caspase-8, as well as NK cell activation, which produce type II interferons. 10, 11 IFNa/b also modulates activation of CD8 + T lymphocytes and produces additional IFNg, as well as engages distant antiviral responses to signal Jak1 and Tyk2 phosphorylation to initiate various STAT pathways. 4, 5, 7, 10 The importance of interferons in building immune integrity is highlighted by their overlap with humoral immunity, and their need in promoting the cytotoxic T-cell response, as demonstrated in the aforementioned hepatitis and cervical cancer treatment models. 12, 13 With respect to its antitumor effects, IFNa affects intrinsic differentiation, apoptosis, growth inhibition, cell migration, and production of secondary mediators. Additionally, it stimulates immune regulation by means of increased antigenic expression, antigen-presenting cell activation, myeloidderived suppressor cell inhibition, and upregulation of stress ligands. 5 Nonetheless, literature is lacking regarding the integrity of interferon's immune-modulating actions in a compromised immune system.
In all patients in our study, OSSN partially or completely responded to 5-FU after an insufficient response to IFNa2b, and one responded to MMC. This may be explained by different mechanisms of action of 5-FU and MMC when compared with interferon. IFNa works on immunological factors, whereas MMC and 5-FU inhibit nucleic acid synthesis. 14, 15 In conclusion, our case series highlights that immunosuppression may be a risk factor for treatment failure of IFNa2b in OSSN. Our findings are supported by risk factors for treatment failure in hepatitis C and cervical intraepithelial neoplasia and by the known interface of type I interferon within a complex immune system. However, our study's conclusions must be evaluated within its limitations, which include a retrospective design with a limited number of patients. Based on this study, we are unable to comment on whether there is a differential treatment response by HIV status, as none of the patients presented in this series were HIV positive. Additionally, it is important to consider other possible factors that could affect the treatment response, such as age, medication compliance, and genetic/cytogenetic contributions. Despite these limitations, our study suggests that topical IFNa2b may not be the optimal choice for patients with OSSN and immunosuppression due to a hematologic malignancy. In these patients, a surgical excision or another medical therapy (eg, 5-FU or MMC) may be a better first-line therapeutic option. Further large-scale studies are necessary to confirm our findings. 
